NVDA
NVIDIA
-- 139.670 TSLA
Tesla
-- 430.600 PLTR
Palantir
-- 80.690 AMD
Advanced Micro Devices
-- 124.600 RGTI
Rigetti Computing
-- 10.9600 
NEWS
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
Tuesday, 17th December at 8:30 am
Agreement to Deliver Critical Medicines
ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (NASDAQ: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market is pleased to announce that Hupan Pharmaceutical has signed a Sales Agreement (the "Agreement") with Sinopharm Holding Hubei New Special Medicine Co., Ltd. ("Sinopharm Hubei"), a subsidiary of Sinopharm Group. The Agreement, valued at approximately RMB 11.0 million(approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.
This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services. These achievements reflect Hupan Pharmaceutical's expanding role as a reliable provider of pharmaceutical solutions in China.
"We are excited to strengthen our relationship with Sinopharm Group further, a leading global player in the healthcare industry," said Lan Su, COO of Lakeside Holding Limited. "This Agreement demonstrates our capabilities in delivering high-quality pharmaceutical products, ensuring reliable supplies of essential medicines. We remain committed to broadening our portfolio and expanding our market reach, enhancing our role as a trusted pharmaceutical solutions provider."
Tuesday, 17th December at 8:30 am
Agreement to Deliver Critical Medicines
ITASCA, Ill., Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (NASDAQ: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market is pleased to announce that Hupan Pharmaceutical has signed a Sales Agreement (the "Agreement") with Sinopharm Holding Hubei New Special Medicine Co., Ltd. ("Sinopharm Hubei"), a subsidiary of Sinopharm Group. The Agreement, valued at approximately RMB 11.0 million(approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.
This Agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services. These achievements reflect Hupan Pharmaceutical's expanding role as a reliable provider of pharmaceutical solutions in China.
"We are excited to strengthen our relationship with Sinopharm Group further, a leading global player in the healthcare industry," said Lan Su, COO of Lakeside Holding Limited. "This Agreement demonstrates our capabilities in delivering high-quality pharmaceutical products, ensuring reliable supplies of essential medicines. We remain committed to broadening our portfolio and expanding our market reach, enhancing our role as a trusted pharmaceutical solutions provider."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment